KDR and gastric cancer: In addition, the recent phase III study of apatinib [13], an oral small molecule VEGFR-2 TKI, in Chinese patients with advanced GC, demonstrated prolonged median OS in the apatinib arm of 195 versus 140 days in the placebo arm (HR 0.71, 95 % CI 0.54–0.94, P < 0.0001).